Kestra Medical Technologies (KMTS) director sells 15,000 shares in planned trade

Rhea-AI Filing Summary

Kestra Medical Technologies director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares on April 15, 2026 at a weighted average price of $20.0447 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Webster now holds 349,786 common shares directly.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares ($300,671)

Net Sell 1 txn

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($301K)

Type	Security	Shares	Price	Value
Sale	Common Shares	15,000	$20.0447	$301K

Holdings After Transaction: Common Shares — 349,786 shares (Direct)

Footnotes (1)

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.0000 to $20.2200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Shares sold: 15,000 shares Weighted average sale price: $20.0447 per share Post-transaction holdings: 349,786 shares +2 more

5 metrics

Shares sold 15,000 shares Open-market sale on April 15, 2026

Weighted average sale price $20.0447 per share Common shares sold in multiple trades

Post-transaction holdings 349,786 shares Common shares held directly after sale

Price range $20.0000–$20.2200 per share Range of execution prices for reported sales

Rule 10b5-1 plan adoption date September 29, 2025 Plan governing the reported sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	04/15/2026	04/15/2026	S(1)		15,000	D	$20.0447(2)	349,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.0000 to $20.2200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KMTS director Brian Daniel Webster report?

Brian Daniel Webster reported selling 15,000 KMTS common shares in an open-market transaction. The sale occurred at a weighted average price of $20.0447 per share, and was disclosed as a routine Form 4 insider transaction to the SEC.

At what price were the Kestra Medical Technologies (KMTS) shares sold?

The KMTS shares were sold at a weighted average price of $20.0447 per share. According to the filing, individual sale prices ranged from $20.0000 to $20.2200, and detailed price breakdowns are available upon request from the reporting person.

How many Kestra Medical Technologies shares does Brian Daniel Webster hold after this sale?

After the reported sale, Brian Daniel Webster holds 349,786 KMTS common shares directly. This figure reflects his remaining ownership position following the 15,000-share open-market sale reported in the Form 4 insider trading disclosure.

Was the KMTS insider sale made under a Rule 10b5-1 trading plan?

Yes, the KMTS insider sale was made under a Rule 10b5-1 trading plan. The filing states the transaction occurred pursuant to a plan that Brian Daniel Webster adopted on September 29, 2025, indicating it was a pre-arranged, scheduled trading program.

What does the weighted average sale price mean in the KMTS Form 4 filing?

The weighted average price of $20.0447 represents the average price across multiple trade executions. The filing notes that individual sale prices ranged from $20.0000 to $20.2200, and the exact number of shares sold at each price is available upon request.